Journal style

Tables should be simple and no duplicate information should appear in the text of the article. Tables should be numbered consecutively and headed by a concise title.
Place explanatory matter in footnotes, not in the heading. Explain in footnotes allnon-standard abbreviations that are used in each table. For footnotes use the followingsymbols in this sequence.
Complete sets of illustrations must be submitted with legends typed on the same page. Only clear photographs are acceptable. All lettering must be legible afterreduction to column size. Magnification and staining should be indicated whenpertinent.
Use only standard abbreviations. Avoid abbreviations in the title and abstract.
The full term for which an abbreviation stands should precede its first use in the textunless it is a standard unit of measurement.
For experimental investigations of human subjects, state in the Methods section that an appropriate institutional review board approved the project. For thoseinvestigators who do not have formal ethics review committees, the principlesoutlined in the Declaration of Helsinki 2 should be followed. For investigations ofhuman subjects, state in the Methods section the manner in which informed consentwas obtained from the study participants.
Include a signed statement of informed consent to publish (in print and online) patient descriptions, photographs and pedigrees from all persons (parents or legalguardians for minors) who can be identified in such written descriptions, photographs,or pedigrees. Such persons should be shown the manuscript before its submission.
Acknowledge all text, illustrations and tables adapted or reproduced from other publications and submit permission from the original publishers (or other copyrightowner) to republish in print, online, and licensed versions of Infection International(Electronic Edition).
Number references in the order they appear in the text; do not alphabetize. In text, tables and legends, identify references with superscript Arabic numerals. When listing
references, abbreviate titles of journals according to Medline. Not
ot : List authors
and/or editors up to 3; if more than 3, list the first 3 authors followed by et al.
Liu XP, Long DY, Dong JZ, et al. Recurrent atrial tachycardia and atrialfibrillation after circumferential pulmonary vein ablation: What’s the difference?Chin Med J,2005,118(21):1773-1778.
Svetitsky S, Leibovici L, Paul M. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob AgentsChemother,2009,53(10):4069-4079.
Xie SZ, Gu MJ, Cheng YP. Inhibitory effect of medroxyprogesterone acetate onangiogenesis induced by malignant neoplasm. Chin J Obstet Gynecol(Chin)*,1998,33(2):113-114.
Dannenberg AM. Immune mechanisms in the pathogenesis of pulmonarytuberculosis. Rev Infect Dis,1989,11 (Suppl 2):s369-s378.
Ozben T, Nacitarhan S, Tuncer N. Plasma and urine sialic acid in non-insulindependent diabetes mellitus. Ann Clin Biochem,1995,32 (Pt 3):303-306.
Cumulative number of reported cases of severe acute respiratory syndrome(SARS). Geneva: World Health Organization, 2003. (Accessed April 9, 2003 at.) * : It is especially needed to note “(Chin)” for articles published in Chinese.
Authors are responsible for the accuracy and completeness of their references and Include a structured abstract of no more than 300 words for original articles, brief report (Background, Methods, Results, Conclusions) and review articles(Objective, Data sources, Study selection, Results, Conclusions); an informativeabstract for viewpoint and case report.
Three to 6 words or short phrases should be provided at the top of the abstract page as keywords. Terms from the medical subject heading (MeSH) list of Medlineshould be used; if suitable MeSH terms are not yet available for recently introducedterms, present terms may be used.
Introduction should be short and arresting. State the purpose of the article and summarize the rationale for the study or observation. Give only strictly pertinentreferences and do not include data or conclusions from the work being reported.
Describe your selection of the observational or experimental subjects (patients or laboratory animals, including controls) clearly. Identify the age, sex, and otherimportant characteristics of the subjects.
Identify the methods, apparatus (list the manufacturer’s name and original country in parentheses), and procedures in sufficient detail to allow other workers toreproduce the results. Give references to established methods, including statisticalmethods; provide references and brief descriptions for methods that have beenpublished but are not well known; describe new or substantially modified methods, give reasons for using them, and evaluate their limitations. Identify precisely all drugsand chemicals used, including generic name (s), dose (s), and route (s) ofadministration.
Reports of randomized clinical trials should present information on all major study elements including the protocol (study population, interventions or exposures,outcomes, and the rationale for statistical analysis), assignment of interventions(methods of randomization, concealment of allocation to treatment groups), and themethod of masking (blinding).
Overall describe the major findings of the study. Present your results in logical sequence in the text, tables and illustrations. Do not repeat in the text all the data inthe tables or illustrations; emphasize or summarize only important observations.
Summarize the major findings. Discuss possible problems with the methods used.
Compare your results with previous work. Discuss the clinical and scientific (if any)implications of your findings and their limitations. Suggest further work. Produce asuccinct conclusion.


Microsoft word - ecn urology nssg minutes 130212.doc

ESSEX CANCER NETWORK UROLOGY NSSG MEETING Monday 13th February 2012 14.00 – 16.00 hrs Swift House, Middle & Annexe Chelmsford CM2 5PF Present: Tom Carr (Chair) Medical Director, ECN Consultant Urologist, BTUHFT CNS, SUHFT David Tsang Clinical Oncologist, SUHFT Maggie Braithwaite CNS, CHUFT Claire Turner CNS, MEHT Chris Stubbi

DOENÇA METABÓLICA ÓSSEA DA PREMATURIDADE Miza Mª Barreto A. Vidigal Capítulo do livro Assistência ao Recém-Nascido , editado por Paulo R. Margotto, 2ª Edição DEFINIÇÃO Conjunto de condições que determinam alterações no processo de mineralização óssea levando a fragilidade do suporte estrutural deste e nos casos mais graves, pode ocasionar o aparecimento de fratu

Copyright © 2010-2014 Metabolize Drugs Pdf